Multiple Myeloma · line 1 · Lenalidomide + Dexamethasone continuous (Rd, MAIA control arm — MM 1L transplant-ineligible)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 1 |
|---|---|
| Voie | standard |
| Régime lié | REG-RD-CONTINUOUS |
| ID | IND-MM-1L-RD |
|---|---|
| Type | Indication |
| État | reviewed 2026-05-09 | pending_clinical_signoff |
| Maladies | DIS-MM |
| Sources | SRC-MAIA-FACON-2019 SRC-NCCN-MM-2025 |
Notes
STUB — requires clinical co-lead signoff before publication. Standard counterpart to IND-MM-1L-DARA-RD for two-plan output in transplant- ineligible NDMM (CHARTER §2). Rd continuous is the standard-access option when daratumumab funding is unavailable (common in Ukraine where НСЗУ does not currently reimburse daratumumab). MAIA trial context (Facon NEJM 2019, PMID 30926586): this indication represents the control arm — Rd alone. D-Rd improved PFS HR 0.56 and 5-yr OS HR 0.66 vs Rd. In a well-resourced setting, D-Rd is preferred; Rd is the fallback when daratumumab is inaccessible. FIRST trial (Benboubker NEJM 2014, PMID 25184863): Rd continuous vs Rd18 (18 cycles fixed) vs MPT — Rd continuous showed superior PFS (26 months) vs MPT (21.9 months). Established the "until progression" strategy. Scope gate: fit_for_transplant: false restricts IND-MM-1L-RD to transplant-ineligible patients. For transplant-eligible standard-plan patients, see IND-MM-1L-VRD (VRd backbone + ASCT pathway).
Utilisé par
Algorithmes
ALGO-MM-1L- ALGO-MM-1L
Indication
IND-MM-1L-DARA-RD- IND-MM-1L-DARA-RD